On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...